



- (51) **International Patent Classification:**
C08B 37/16 (2006.01) A61K 47/40 (2006.01)
- (21) **International Application Number:**
PCT/CA2015/050254
- (22) **International Filing Date:**
31 March 2015 (31.03.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/004,364 29 May 2014 (29.05.2014) US
62/060,787 7 October 2014 (07.10.2014) US
- (71) **Applicant:** UTI LIMITED PARTNERSHIP [CA/CA];
3353 - 31st Street, NW, Calgary, Alberta T2L 2K7 (CA).
- (72) **Inventors:** LING, Chang-Chun; 235 Hawkwood Drive
NW, Calgary, Alberta T3G 3M9 (CA). ZHANG, Ping;
235 Hawkwood Drive NW, Calgary, Alberta T3G 3M9
(CA).
- (74) **Agents:** OSLER, HOSKIN & HARCOURT LLP et al.;
Suite 1900, 340 Albert Street, Ottawa, Ontario K1R 7Y6
(CA).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2015/179963 A1

(54) **Title:** CYCLODEXTRIN-BASED POLYANIONIC AND NON-IONIC DENDRIMERS

(57) **Abstract:** The present application provides polyanionic and non-ionic cyclodextrin-based compounds, and methods of manufacturing them. The compounds comprise a negatively-charged or neutral moiety (and, for polyanionic compounds, a suitable counter cation), one or more linkers, optionally one or more bridging groups, a cyclodextrin, and one or more substituents on the cyclodextrin. The compounds can be used in pharmaceutical compositions, and as excipients or carriers of guest molecules.

CYCLODEXTRIN-BASED POLYANIONIC AND NON-IONIC DENDRIMERS

FIELD

[0001] The present application pertains to the field of cyclodextrins. More particularly, the present application relates to cyclodextrin-based polyanionic and non-ionic dendrimers for use in pharmaceutical applications.

BACKGROUND

[0002] Cyclodextrins (CDs) are a class of non-toxic, water-soluble D-glucose based macrocycles with a hydrophobic cavity. CDs typically vary by the number of glucose units. Common members include α -CD (6 glucose units), β -CD (7 glucose units) and γ -CD (8 glucose units), with increasing cavity size. The varying cavity sizes offer increased utility in a wide variety of applications, particularly in drug delivery models. For example, CDs can be used to form "inclusion complexes" in which a drug is included and carried within the cavity. This can be used as a pharmaceutical excipient to improve drug water solubility, chemical stability, and removal of certain drug side effects (such as undesirable taste). CDs have also drawn interest in the cosmetic and food additives industries, in the design of artificial enzymes, gene delivery vehicles, sensors and novel supramolecular assemblies.

[0003] CDs can be native or chemically modified on either or both of their primary and/or secondary faces. Typically, an inclusion complex often has lower water solubility than native CDs. Chemical modifications of CDs can change their physico-chemical properties. For example, adding a tosyl group on the primary face of the β -CD renders the molecule near insoluble at room temperature, while adding methyl groups at OH-6 and OH-2 positions significantly increases water solubility. The toxicity of the molecule can also be changed. Therefore, modification of the CD molecule may present certain advantages. However, chemical modification of CDs is typically difficult to achieve, often leading to the formation of a mixture of products that are difficult to separate.

[0004] The groups added to the primary or second face can be neutral or charged. For example, Captisol® is an excipient for use with a number of drugs. It is a polyanionic mixture of β -CD derivative having from 1 to 10 sodium sulfobutyl ether groups directly attached via oxygen atoms of the D-glucose thereto (US Patent No. 5,134,127 (Stella et al)).

5 Captisol is prepared by reacting a β -CD with 1,4-butyl sultone and sodium hydroxide in water. The obtained product is a mixture containing many positional and regioisomers with varying degrees of substitution at different oxygen positions on the CD, such as substitution at O-2, O-3 and O-6 on the CD. (Luna, *et al.*, *Carbohydr. Res.*, 299, 103-110, 1997; Luna, *et al.*, *Carbohydr. Res.*, 299, 111-118, 1997; Rogmann *et al.*, *Carbohydr. Res.*, 327, 275-285,

10 2000; <http://www.captisol.com/faq/solution-and-solid-state-characteristics-in-captisol>).

[0005] There are certain disadvantages with Captisol. As it comprises a mixture of compounds, thus resulting in varied compositions, it is difficult if not impossible to define and characterize the product compositions.

[0006] Another polyanionic CD compound currently on the market is Sugammadex (by

15 Merck), which is a polyanionic agent obtained from γ -CD. Sugammadex blocks the activity of neuromuscular agents (Yan, *et al.*, *Drugs*, 2009: 69, 919-42; Calderón-Acedos, *et al.*, *Eur. J. Hosp. Pharm.* 2012: 19, 248). See also US Patent No. 6,670,340 (Zhang et al.) and US Patent No. 6,949,527 (Zhang et al.).

[0007] Non-ionic CD-based compounds are also known in the art. One example includes

20 hydroxypropyl-beta CD (HPBCD). However, this exists in a mixture of compounds, similarly resulting in varied compositions.

[0008] There is a need for pure anionic or non-ionic CD derivatives for various applications in the pharmaceutical industry, such as those described herein, for example.

[0009] This background information is provided for the purpose of making known

25 information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention.

SUMMARY

[0010] An object of the present invention is to provide improved pure polyanionic and non-ionic cyclodextrin-based compounds, which can be used in various pharmaceutical related applications.


- 5 [0011] In accordance with an aspect of the present invention, there is provided a polyanionic cyclodextrin-based compound of the formula



- 10 wherein $X^{(-)}$ is one or more negatively charged moieties, $Y^{(+)}$ is one or more counter cations, L is one or more linkers, G is a bond or is one or more bridging groups, D is a cyclodextrin, and R is one or more substituents.


[0012] The charged moiety $X^{(-)}$ can be any suitable negatively charged moiety. Non-limiting examples include $-\text{SO}_3^-$, $-\text{CO}_2^-$, $-\text{OSO}_3^-$, $-\text{OPO}_3^-$, for example.

- 15 [0013] The linker L can comprise a substituted or unsubstituted alkyl group (such as a C_1 - C_{11} alkyl group, for example), and/or a substituted or unsubstituted polyethylene glycol (PEG) group, or a combination of one or more alkyl groups and one or more PEG groups. In an exemplary embodiment, the PEG group is of the formula $-\text{CHZ}(\text{CH}_2\text{OCHZ})_m\text{CH}_2-$ where Z is H or CH_3 and m is 1 to 20, for example; however, any suitable PEG group, if present, may be contemplated. In certain embodiments, L can comprise any unsubstituted or substituted alkyl group; for example, the alkyl group may be substituted with a PEG group. However, 20 any suitable substituent may be contemplated. In other embodiments, L can comprise an unsubstituted or substituted PEG group; for example, the PEG group may be substituted with one or more alkyl groups. However, any suitable substituent may be contemplated. In certain other embodiments, L comprises a PEG group which has none, or one or more alkyl groups flanking on either or both sides of the PEG group. One or more of the CH_2 groups of 25 the alkyl group may be replaced with an atom or functional group. Non-limiting examples of the atom or functional group include $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{CONH}-$, $-\text{COO}-$, $-\text{NZ}-$, or a substituted or unsubstituted 1,2,3-triazole group, for example. Examples of substituted 1,2,3-triazole groups may include those substituted with a group comprising one of the following structures:



[0014] The cyclodextrin D can comprise, for example, 6, 7, or 8 glucose subunits, typically 7.

[0015] In certain embodiments, G represents any one or more suitable bridging groups. G may represent, for example, an ester, amide, amine, sulfur, or a substituted or unsubstituted 1,2,3-triazole. Non-limiting examples of bridging groups for G include -S-, -OC(O)-, -NHC(O)-, -SO-, -SO₂-, or a substituted or unsubstituted 1,2,3-triazole group. Examples of substituted 1,2,3-triazole groups may include those substituted with a group comprising one of the following structures:




However, other suitable bridging groups may be contemplated. In certain other embodiments, G is a bond.

[0016] The substituent R can be any one or more suitable substituents. Non-limiting examples include H, an optionally substituted alkyl group or an optionally substituted acyl group. In certain embodiments, the optionally substituted alkyl group or acyl group is a C₁-C₁₈ group, for example.

[0017] Y⁽⁺⁾ can be any pharmaceutically acceptable cation, typically Na⁺ or K⁺, for example.

[0018] In certain embodiments, the polyanionic cyclodextrin (CD)-based compound is:



(II)

where R, L, G, X⁽⁻⁾ and Y⁽⁺⁾ are defined above and wherein the cyclodextrin subunit is shown where p is 6, 7 or 8, typically 7.


[0019] In accordance with another aspect there is provided a non-ionic cyclodextrin-based compound of the formula



wherein X' is one or more neutral moieties; L is one or more linkers; G is a bond or is one or more bridging groups; D is a cyclodextrin; and R is one or more substituents.

[0020] Examples of X' may include, for example, an unsubstituted or substituted amide including its N-substituted forms (such as $-\text{CONH}_2$, for example), a nitrile group ($-\text{CN}$), or a polyhydroxylated residue (such as a carbohydrate for example).


[0021] The linker L can comprise a substituted or unsubstituted alkyl group (such as a C_1 - C_{11} alkyl group, for example), and/or a substituted or unsubstituted polyethylene glycol (PEG) group, or a combination of one or more alkyl groups and one or more PEG groups. In an exemplary embodiment, the PEG group is of the formula $-\text{CHZ}(\text{CH}_2\text{OCHZ})_m\text{CH}_2-$ where Z is H or CH_3 and m is 1 to 20, for example; however, any suitable PEG group, if present, may be contemplated. In certain embodiments, L can comprise any unsubstituted or substituted alkyl group; for example, the alkyl group may be substituted with a PEG group. However, any suitable substituent may be contemplated. In other embodiments, L can comprise an unsubstituted or substituted PEG group; for example, the PEG group may be substituted with one or more alkyl groups. However, any suitable substituent may be contemplated. In certain other embodiments, L comprises a PEG group which has none, or one or more alkyl groups flanking on either or both sides of the PEG group. One or more of the CH_2 groups of the alkyl group may be replaced with an atom or functional group. Non-limiting examples of the atom or functional group include $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{CONH}-$, $-\text{COO}-$, $-\text{NZ}-$, or a substituted or unsubstituted 1,2,3-triazole. Examples of substituted 1,2,3-triazole groups may include those substituted with a group comprising one of the following structures:



[0022] The cyclodextrin D can comprise, for example, 6, 7, or 8 glucose subunits, typically 7.

[0027] The present application also provides a method of synthesizing the polyanionic or non-ionic cyclodextrin-based compounds, substantially as described herein.


[0028] In one aspect, there is provided a method of synthesizing a polyanionic compound as described herein, comprising reacting alkyl sultones of the formula:



with a salt of thioacetate (AcS^-M^+) where M^+ is a counter cation such as Na^+ or K^+ , which generates a compound of the formula:



as a reagent to react with a compound of the formula:



where X'' is a halide such as Cl, Br, or I, p is 6 to 8, in an alcohol solvent (such as methanol, for example) together with a polar solvent (such as DMSO, for example), using a base (such as an alkoxide, for example) to obtain a polyanionic cyclodextrin-based compound. In certain embodiments, L is $-(\text{CH}_2)_w-$, where w is 1 to 3; R is H; and G is $-\text{S}-$.

15 [0029] The compounds as described herein can be used in various pharmaceutical applications, such as excipients or by inclusion with other molecules. In one example, a cyclodextrin as described herein can be included with cholic acid.

BRIEF DESCRIPTION OF THE FIGURES

[0030] For a better understanding of the present invention, as well as other aspects and further features thereof, reference is made to the following description which is to be used in conjunction with the accompanying drawings, where:

5 [0031] Figure 1 shows an exemplary representation of thioether-linked sulfoalkyl polyanionic CD-based compounds.

[0032] Figure 2 shows another exemplary representation of thioether-linked polyanionic CDs with an additional PEG-ylated linker group.

10 [0033] Figure 3 shows an exemplary synthesis of thioether-linked sulfoalkyl polyanionic CDs.

[0034] Figure 4 shows an exemplary synthesis of thioether-linked sulfoalkyl analogs.

[0035] Figure 5 shows an exemplary synthesis of thioether-linked carboxyalkyl analogs.

[0036] Figure 6 shows exemplary polyanionic sulfoPEG thioether cyclodextrins.

[0037] Figure 7 shows exemplary sulfoPEG thioether cyclodextrin analogs.

15 [0038] Figure 8 shows an exemplary synthesis of sulfoalkyl thioether analogs.

[0039] Figure 9 shows an exemplary non-ionic analogs

[0040] Figure 10 shows an exemplary synthesis of non-ionic polyamide analogs containing PEG residues and preparation of the required reagents.

20 [0041] Figure 11 shows an ^1H NMR spectrum for a polyanionic α -CD derivative (structure 28).

[0042] Figure 12 shows variable temperature ^1H NMR experiments of an α -CD derivative (structure 28).

[0043] Figure 13 shows an ^1H NMR spectrum of polyanionic β -CD derivative (structure 29).

[0044] Figure 14 shows an ^1H NMR spectrum of polyanionic γ -CD derivative (structure 30).

[0045] Figure 15 shows an ^1H NMR spectrum of non-ionic γ -CD polyamide derivative (structure 39).

[0046] Figure 16 shows an ^1H NMR spectrum of non-ionic PEGylated γ -CD polyamide derivative (structure 43).

5 [0047] Figure 17 shows an ^1H NMR spectrum of polyanionic β -CD derivative (structure 29) forming an inclusion complex with cholic acid.

[0048] Figure 18 shows an ^1H NMR spectrum of polyanionic γ -CD derivative (structure 30) forming an inclusion complex with cholic acid.

10 [0049] Figure 19 shows the expanded ^1H NMR spectrum of the polyanionic γ -CD derivative (structure 30) forming an inclusion complex with cholic acid.

DETAILED DESCRIPTION

[0050] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

15 [0051] As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.

[0052] The term “comprising” as used herein will be understood to mean that the list following is non-exhaustive and may or may not include any other additional suitable items, for example one or more further feature(s), component(s) and/or ingredient(s) as appropriate.

20 [0053] As used herein, the term “aliphatic” refers to a linear, branched or cyclic, saturated or unsaturated non-aromatic hydrocarbon. Examples of aliphatic hydrocarbons include alkyl groups.

[0054] As used herein, the term “alkyl” refers to a linear, branched or cyclic, saturated or unsaturated hydrocarbon group which can be unsubstituted or is optionally substituted with
25 one or more substituent. Examples of saturated straight or branched chain alkyl groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-1-butyl, 3-methyl-1-butyl,

2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-1-pentyl,
3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl,
4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl and 2-ethyl-1-butyl, 1-heptyl
and 1-octyl. As used herein the term “alkyl” encompasses cyclic alkyls, or cycloalkyl
5 groups. The term “cycloalkyl” as used herein refers to a non-aromatic, saturated monocyclic,
bicyclic or tricyclic hydrocarbon ring system containing at least 3 carbon atoms. Examples
of C₃-C₁₂ cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, adamantyl, bicyclo[2.2.2]oct-2-
enyl, and bicyclo[2.2.2]octyl. Chemical functional groups, such as ether, thioether, sulfoxide,
10 or amine, amide, ammonium, ester, phenyl, 1,2,3-triazole etc can be incorporated alkyl group
to help extend the length of the chain.

[0055] As used herein, the term “substituted” refers to the structure having one or more
substituents. A substituent is an atom or group of bonded atoms that can be considered to
have replaced one or more hydrogen atoms attached to a parent molecular entity. Examples
15 of substituents include aliphatic groups, halogen, arylcarbonyloxy, alkoxy carbonyloxy,
aryloxy carbonyloxy, alkoxy carbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate
ester, phosphonato, phosphinato, cyano, tertiary amino, tertiary acylamino, tertiary amide,
imino, alkylthio, arylthio, sulfonato, sulfamoyl, tertiary sulfonamido, nitrile, trifluoromethyl,
heterocyclyl, aromatic, and heteroaromatic moieties, ether, ester, boron-containing moieties,
20 tertiary phosphines, and silicon-containing moieties.

[0056] As used herein, the term “hydrophilic” refers to the physical property of a molecule or
chemical entity or substituent within a molecule that tends to be miscible with and/or
dissolved by water, or selectively interacts with water molecules. Hydrophilic groups can
include polar groups. By contrast, as used herein, the term “hydrophobic” refers to the
25 physical property of a molecule or chemical entity or substituent within a molecule that tends
to be immiscible with and/or insoluble in water, or selectively repels water molecules.

[0057] As used herein, the term “amphiphilic” refers to the physical property of a molecule
or chemical entity that possesses both hydrophilic and hydrophobic properties.

[0058] As used herein, the term “anionic” refers to a negatively charged molecule or part
30 thereof which imparts the negative charge.

[0059] In the present document, the hydrophobic groups are illustrated to be placed at the secondary face of a CD while the hydrophilic groups are placed at the primary face of a CD. These two groups can be swapped to link to the opposite face of a CD.

[0060] The present application provides polyanionic and non-ionic CD-based compounds,
5 ideally in a pure form.

[0061] The present application also provides a pharmaceutical composition comprising a medicament and a polyanionic or non-ionic CD-based compound as described herein. The present application also provides the polyanionic or non-ionic compound as described herein as an excipient and/or as carriers of guest molecules.

10 [0062] Ideally, the polyanionic and non-ionic CD-based compounds as described herein can use thioether or its oxidized form (sulfone or sulfoxide) as the linking group instead of ether as done previously in the art. This results in structurally well-defined polyanionic and non-ionic CD-based compounds in pure form that are easier to characterize. As such, the polyanionic and non-ionic CD-based compounds of the present application are suitable for
15 generating drug formulations in well-defined compositions.

[0063] Advantageously, the present polyanionic and non-ionic CD-based compounds can bind to other molecules with better affinity due to the symmetric nature of the cavity within the CD. The cavity can accommodate larger or smaller molecules as the polyanionic or non-ionic CD can be an α , β , or γ analog.

20 [0064] The polyanionic and non-ionic CD-based compounds can be designed to be either totally water-soluble (with short chains, where R is H, methyl to n-propyl, or acetyl to n-propanoyl) or self-assemble (with longer chains, where R is n-butyl to n-octadecyl or n-butanoyl to n-octadecanoyl) to form nanoparticles (micelles) in water. These structures ideally bind to hydrophobic drug molecules with better affinities because of the alkyl chains
25 and the PEG linker groups.

[0065] Polyanionic CD-based compounds


[0066] In accordance with one aspect, there is provided a polyanionic cyclodextrin-based compound of the formula



wherein $X^{(-)}$ is one or more negatively charged moieties, $Y^{(+)}$ is one or more counter cations, L is one or more linkers, G is a bond or is one or more bridging groups, D is a cyclodextrin, and R is one or more substituents.

[0067] The charged moiety $X^{(-)}$ can be any suitable negatively charged moiety. Non-limiting examples include $-\text{SO}_3^-$, $-\text{CO}_2^-$, $-\text{OSO}_3^-$, $-\text{OPO}_3^-$, for example.


[0068] The linker L can comprise a substituted or unsubstituted alkyl group (such as a C_1 - C_{11} alkyl group, for example), and/or a substituted or unsubstituted polyethylene glycol (PEG) group, or a combination of one or more alkyl groups and one or more PEG groups. In an exemplary embodiment, the PEG group is of the formula $-\text{CHZ}(\text{CH}_2\text{OCHZ})_m\text{CH}_2-$ where Z is H or CH_3 and m is 1 to 20, for example; however, any suitable PEG group, if present, may be contemplated. In certain embodiments, L can comprise any unsubstituted or substituted alkyl group; for example, the alkyl group may be substituted with a PEG group. However, any suitable substituent may be contemplated. In other embodiments, L can comprise an unsubstituted or substituted PEG group; for example, the PEG group may be substituted with one or more alkyl groups. However, any suitable substituent may be contemplated. In certain other embodiments, L comprises a PEG group which has none, or one or more alkyl groups flanking on either or both sides of the PEG group. One or more of the CH_2 groups of the alkyl group may be replaced with an atom or functional group. Non-limiting examples of the atom or functional group include $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{CONH}-$, $-\text{COO}-$, $-\text{NZ}-$, or a substituted or unsubstituted 1,2,3-triazole group, for example. Examples of substituted 1,2,3-triazole groups may include those substituted with a group comprising one of the following structures:



[0069] The cyclodextrin D can comprise, for example, 6, 7, or 8 glucose subunits, typically 7.

[0070] In certain embodiments, G represents any one or more suitable bridging groups. G may represent, for example, an ester, amide, amine, sulfur, or a substituted or unsubstituted 1,2,3-triazole. Non-limiting examples of bridging groups for G include $-\text{S}-$, $-\text{OC}(\text{O})-$, $-\text{NHC}(\text{O})-$, $-\text{SO}-$, $-\text{SO}_2-$, or a substituted or unsubstituted 1,2,3-triazole group. Examples of

substituted 1,2,3-triazole groups may include those substituted with a group comprising one of the following structures:




. However, other suitable bridging groups may be contemplated. In certain other embodiments, G is a bond.

- 5 [0071] The substituent R can be any one or more suitable substituents. Non-limiting examples include H, an optionally substituted alkyl group or an optionally substituted acyl group. In certain embodiments, the optionally substituted alkyl group or acyl group is a C₁-C₁₈ group, for example.

[0072] Y⁽⁺⁾ can be any pharmaceutically acceptable cation, typically Na⁺ or K⁺, for example.

- 10 [0073] In certain embodiments, the polyanionic cyclodextrin (CD)-based compound is:



(Formula II)

where R, L, G, X⁽⁻⁾ and Y⁽⁺⁾ are defined herein and wherein the cyclodextrin subunit is shown where p is 6 to 8, typically 7.

- 15 [0074] The number of linkers attached to the cyclodextrin can vary but are typically the same length within a given CD-based molecule.

[0075] The CD core (i.e., D) comprises any number of glucose subunits. In certain embodiments, there are 6, 7, or 8 glucose subunits, typically 7. Therefore, in certain embodiments, a β-CD is contemplated.

- 20 [0076] On the secondary face of the CD are attached one or more, typically a plurality of substituents, R. The substituents can be H, an alkyl or acyl group. In certain embodiments,

the chains are bonded to either O2 or O3 of the CD group, or both O2 and O3 groups. The length of the group can vary from C₁-C₁₈, for example.

[0077] Non-ionic CD-based compounds


[0078] In accordance with another aspect, there is provided a non-ionic cyclodextrin-based
5 compound of the formula



wherein X' is one or more neutral moieties; L is one or more linkers; G is a bond or is one or more bridging groups; D is a cyclodextrin; and R is one or more substituents.


[0079] Examples of X' may include, for example, an unsubstituted or substituted amide
10 including its N-substituted forms (such as -CONH₂, for example), a nitrile group (-CN), or a polyhydroxylated residue (such as a carbohydrate for example).

[0080] The linker L can comprise a substituted or unsubstituted alkyl group (such as a C₁-C₁₁ alkyl group, for example), and/or a substituted or unsubstituted polyethylene glycol (PEG) group, or a combination of one or more alkyl groups and one or more PEG groups. In
15 an exemplary embodiment, the PEG group is of the formula -CHZ(CH₂OCHZ)_mCH₂- where Z is H or CH₃ and m is 1 to 20, for example; however, any suitable PEG group, if present, may be contemplated. In certain embodiments, L can comprise any unsubstituted or substituted alkyl group; for example, the alkyl group may be substituted with a PEG group. However, any suitable substituent may be contemplated. In other embodiments, L can
20 comprise an unsubstituted or substituted PEG group; for example, the PEG group may be substituted with one or more alkyl groups. However, any suitable substituent may be contemplated. In certain other embodiments, L comprises a PEG group which has none, or one or more alkyl groups flanking on either or both sides of the PEG group. One or more of the CH₂ groups of the alkyl group may be replaced with an atom or functional group. Non-
25 limiting examples of the atom or functional group include -O-, -S-, -SO-, -SO₂-, -CONH-, -COO-, -NZ-, or a substituted or unsubstituted 1,2,3-triazole. Examples of substituted 1,2,3-triazole groups may include those substituted with a group comprising one of the following structures:




[0081] The cyclodextrin D can comprise, for example, 6, 7, or 8 glucose subunits, typically 7.

[0082] In certain embodiments, G represents any one or more suitable bridging groups. G may represent, for example, an ester, amide, amine, sulfur, or a substituted or unsubstituted 1,2,3-triazole. Non-limiting examples of bridging groups for G include $-S-$, $-OC(O)-$, $-NHC(O)-$, $-SO-$, $-SO_2-$, or a substituted or unsubstituted 1,2,3-triazole group. Examples of substituted 1,2,3-triazole groups may include those substituted with a group comprising one of the following structures:



[0083] The substituent R can be any one or more suitable substituents. Non-limiting examples include H, an optionally substituted alkyl group or an optionally substituted acyl group. In certain embodiments, the optionally substituted alkyl group or acyl group is a C₁-15 C₁₈ group, for example.

[0084] In certain embodiments, the non-ionic CD-based compound is:



(Formula IV)

[0085] where R, L, G and X' are defined above and wherein the cyclodextrin subunit is shown where p is 6 to 8, typically 7.

[0086] The number of alkyl and/or PEG groups can vary but are typically the same length within a given CD-based molecule.

[0087] EXAMPLES

[0088] Example 1: Polyanionic CD-based compounds and synthesis thereof

- 5 [0089] Figure 1 shows an exemplary thioether-linked sulfoalkyl polyanionic CD-based compound. The molecule comprises a saturation of the CD groups with butyl (tetramethylene) as the linker and thioether as the bridging functionality to connect the linkers to cyclodextrin. The length of the linker can vary. Exemplary R groups on the secondary face of the CD are shown.
- 10 [0090] Figure 2 shows an exemplary polyanionic CD with a PEG-ylated linker group. As shown, the anionic group can be any suitable group, such as $-\text{SO}_3^-$ or $-\text{CO}_2^-$ for example. The PEG segment can include 1 to 20 repeating ethylene glycol groups. Typically, the bridging group used to connect PEG segment to D-glucose is a substituted 1,2,3-triazole group such as the (1,2,3-triazole-4-yl)methyl or (1,2,3-triazole-4-yl)carbonyl group. The
15 compound can be either a water-soluble polyionic cyclodextrin (R = H, methyl to n-butyl) or capable of self-assembling in water (R = longer than n-butyl). Y^+ can be Na^+ , K^+ or any other pharmaceutically tolerated cation.

[0091] Figure 3 shows an exemplary synthesis for polyanionic CD containing sulfoalkyl group via thioether linkage. As shown, the anionic group can be any suitable group, such as
20 $-\text{SO}_3^-$ for example. The leaving group on the cyclodextrin is shown to be bromide, but may also be another conventional halide such as chloride or iodide.

[0092] Figure 4 shows an exemplary synthesis of an amphiphilic sulfoalkyl thioether analog. Ideally, the synthesis requires as little as two steps from a known 2,3-alkylated or acylated CD compound such as compounds 17 or 18. Copper(I)-mediated 1,3-dipolar cycloaddition
25 permits the efficient synthesis of mesylates 19 and 20 from an alkyne-functionalized PEG derivative (16). A highly nucleophilic thiolate containing sulfoalkyl group, generated in situ from the thioacetate precursor, is used to react with the mesylated CD compound to form CDs comprising thioether-linked sulfoalkyls (21, 22).

[0093] Figure 5 shows an exemplary synthesis of a carboxyalkyl thioether analog. A mesylated CD starting material (19, 20) is reacted with an S-thioacetyl-functionalized carboxylic acid to form the carboxyalkyl-functionalized CDs via thioether group (23, 24).

[0094] Example 2: Polyanionic SulfoPEG Thioether Cyclodextrins

5 [0095] Figure 6 shows α , β and γ embodiments of CDs as described herein. In these embodiments, the 6-hydroxyl groups of native cyclodextrins are partially or completely replaced with R groups of the formula $-G-L-X^- Y^+$, $-S-G-L-X^- Y^+$ or $-OH$. G, L, X and Y are as defined above.

[0096] Figure 7 shows examples of synthesized sulfoPEG thioether CD analogs (25-30).

10 Left panel shows two α -CD derivatives (25 and 28) containing different length of linker, middle panel shows two β -CD analogs (26 and 29) and right panel show two γ -CD analogs (27 and 30). In each pair of example shown, the number of PEG group varies between two and three units; however, it may be contemplated as stated above that any number of PEG groups may be present.

15 [0097] Figure 8 shows an exemplary synthesis of sulfoPEG thioether analogs as described herein. Typically, an α,ω -dichloride of a PEG of any length (31,34) is reacted with sodium sulfite to selectively replace one of the chlorides with the sulfonate. The remaining chloride (32, 35) is then substituted with thioacetate. The obtained reagent (33, 36) is then reacted
20 with a cyclodextrin derivative (8-10, derived from 5-7) bearing leaving group(s) (Br) at the primary carbon (C6) under basic condition in an alcohol-dimethyl sulfoxide (DMSO) mixture; the reaction generates a reactive thiolate intermediate from the reagent that attacks the cyclodextrin substrate to provide the anionic cyclodextrin product. Here the per-6-substituted derivatives (25-30) were prepared and obtained in pure form.

[0098] Example 3: Non-ionic CD-based compounds and synthesis thereof

25 [0099] Figure 9 shows α , β and γ embodiments of CDs as described herein. In these embodiments, the 6-hydroxyl groups of native cyclodextrins are partially or completely replaced with R groups of the formula $-G-L-X'$, such as $-S-L-X'$, or with $-OH$. G, L and X' are defined above.

[00100] Figure 10 shows an exemplary synthesis of non-ionic CDs. The reagents include the ω -haloalkanamide (such as the 2-chloroacetamide 37). The halide can be subsequently displaced with a thioacetate to afford the ω -(thioacetyl)alkanamide reagents (such as the 2-thioacetylacetamide 38). Additionally, ester analogs of the ω -haloalkanamide that have PEG chain embedded in any position of the ω -haloalkanoate chain (such as the ω -chlorinated ester 40) can be used. The terminal halide can be substituted with thioacetate to afford the ω -thioacetyl substituted esters (such as compound 41), and a subsequent aminolysis reaction simultaneously converts the ester functionality to the desired amide and also deprotect the thioacetyl group to the reactive thiol (such as compound 42). As with the polyanionic CD, the same 6-halogenated CD compounds can be used as a starting material for the subsequent nucleophilic substitutions. In this example, only a per-6-brominated gamma-CD is shown, but other per-6-halogenated alpha- and beta-CD analogs may also be used for substitutions. As shown, the thioester 38 and thiol 42 were respectively subjected to a treatment with alkoxides in DMSO to generate an intermediate thiolates for reaction with the 6-brominated gamma-CD to obtain the non-ionic compounds 39 and a derivative 43 that has a PEG chain embedded into the linker.

[00101] Example 4: Properties of synthesized SulfoPEG polyanionic derivatives 25-30.

[00102] The synthesized SulfoPEG polyanionic derivatives 25-30 show some difference in their chemical properties.

[00103] Figures 11 and 12 show the ^1H NMR spectra synthesized α -cyclodextrin derivative 28 which showed strong evidence of self-inclusion (one of its side arms bends and enters into the cavity of the molecule) at room temperature, as the observed ^1H NMR spectra showed multiple types of glucosyl units. However, the ^1H NMR spectra became increasingly simpler when the temperature was raised. At 80°C, the ^1H NMR spectrum became symmetric, as only one type of the glucosyl unit was observed.

[00104] However, no evidence of self-inclusion was observed for the other two sulfoPEG polyanionic derivatives with a larger cavity (the β and γ - cyclodextrin derivatives 29-30). Figures 13 and 14 show the ^1H NMR spectra of compound 29 and 30, respectively. Both recorded spectra were observed to be symmetric at room temperature.

[00105] Example 4: Properties of synthesized non-ionic derivatives 39.

[00106] Figures 15 shows the ^1H NMR spectrum of non-ionic gamma-cyclodextrin derivative 39 which showed the expected symmetry, as only one type of the glucosyl unit was observed.

5 [00107] Figures 16 shows the ^1H NMR spectrum of non-ionic gamma-cyclodextrin derivative 43 which showed the expected symmetry as well as the PEG group. Only one type of the glucosyl unit was observed.

[00108] Example 5: Inclusion studies

[00109] Inclusion studies were conducted to determine whether the CD-based
10 polyanionic SulfoPEG thioether described herein are suitable for carrying a guest molecule.

[00110] Figure 17 shows the inclusion studies of sulfoPEG β -cyclodextrin derivatives 29. In these studies, the polyanionic β -CD compound (29) was analyzed both without (top panel) and with (bottom panel) cholic acid included within the CD compound. The results show that a polyanionic CD compound in accordance with the present invention can be used
15 as a carrier of guest molecules. However, it can be contemplated that other polyanionic and non-ionic CD compounds as described herein may also be suitable as a carrier or excipient with other guest molecules.

[00111] Figure 18 and 19 show similar inclusion studies of sulfoPEG γ -cyclodextrin derivative 30 with cholic acid (top panel: compound 30 alone, bottom panel: compound 30
20 with cholic acid).

[00112] Therefore, the present experiments provide exemplary polyanionic and non-ionic CD-based compounds which can be used as excipients and/or carriers of guest molecules in a number of pharmaceutical applications.

[00113] References:

25 US Patent No. 7,632,941, Defaye, J., et al., Cyclodextrin Derivatives, Method for the Preparation thereof and Use thereof for the Solubilization of Pharmacologically Active Substances.

US 12/374,211, Defaye, J. (Centre National de la Recherche Scientifique), Novel Amphiphilic Cyclodextrin Derivatives.

PCT/FR2004/000691, Defaye, J. (Centre National de la Recherche Scientifique), Novel Cyclodextrin Derivatives, Methods for Preparation Thereof and use for the Solubilization of
5 Pharmacologically Active Substances.

US Patent No. 6,670,340, 6-Mercapto-Cyclodextrin Derivatives: Reversal Agents for Drug-Induced Neuromuscular Block.

US Patent No. 6,949,527, 6-Mercapto-Cyclodextrin Derivatives: Reversal Agents for Drug-Induced Neuromuscular Block.

10 DE102010012281, Bichimaier, I., Pharmazeutische zusammensetzungen enthaltend substituiertes 6-deoxy-6-sulfanyl cyclodextrin.

Bull. Chem. Soc. Chim. Fr. 132 (8), 857—866, 1995.

[00114] All publications, patents and patent applications mentioned in this Specification are indicative of the level of skill of those skilled in the art to which this
15 invention pertains and are herein incorporated by reference to the same extent as if each individual publication, patent, or patent applications was specifically and individually indicated to be incorporated by reference.

[00115] The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and
20 scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A polyanionic cyclodextrin-based compound of the formula



wherein

$X^{(-)}$ is one or more negatively charged moieties;

$Y^{(+)}$ is one or more counter cations;


L is one or more linkers;

G is a bond or is one or more bridging groups;

D is a cyclodextrin; and

R is one or more substituents.

2. The compound of claim 1, wherein the compound is




(Formula II)

wherein

p is 6 (α -cyclodextrin), 7 (β -cyclodextrin) or 8 (γ -cyclodextrin).


3. The compound of claim 2, wherein p is 7 (β -cyclodextrin).
4. The compound of any one of claims 1 to 3, wherein $X^{(-)}$ is $-\text{SO}_3^-$, $-\text{CO}_2^-$, $-\text{OSO}_3^-$ or $-\text{OPO}_3^-$.
5. The compound of any one of claims 1 to 4, wherein $Y^{(+)}$ is a pharmaceutically acceptable cation.

6. The compound of claim 4, where $Y^{(+)}$ is Na^+ or K^+
7. The compound of any one of claims 1 to 6, wherein G is $-S-$, $-OC(O)-$, $-NHC(O)-$, $-SO-$, $-SO_2-$, or a substituted or unsubstituted 1,2,3-triazole group.
8. The compound of claim 7, wherein the 1,2,3-triazole group is substituted with one of the following structures:



9. The compound of any one of claims 1 to 6, wherein G is a bond.
10. The compound of any one of claims 1 to 9, wherein L comprises a substituted or unsubstituted alkyl group, a substituted or unsubstituted polyethylene glycol (PEG) group, or a combination of one or more alkyl groups and one or more PEG groups.
11. The compound of claim 10, wherein the PEG group is of the formula $-CHZ(CH_2OCHZ)_mCH_2-$, where Z is H or CH_3 and m is 1 to 20.
12. The compound of claim 10 or 11, wherein the alkyl group is substituted with the PEG group.
13. The compound of claim 10 or 11, wherein the PEG group is substituted with the alkyl group.
14. The compound of any one of claims 10 to 13, wherein L comprises the PEG group flanked by one or more alkyl groups on either or both sides of the PEG group.
15. The compound of any one of claims 10 to 14, wherein the alkyl group is a C_1 - C_{11} alkyl group.
16. The compound of any one of claims 10 to 15, wherein one or more of the CH_2 groups of the alkyl group is replaced with an atom or functional group.
17. The compound of claim 16, wherein the atom or functional group is $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-CONH-$, $-COO-$, $-NZ-$ or a substituted or unsubstituted 1,2,3-triazole.


18. The compound of claim 17, wherein the 1,2,3-triazole group is substituted with one of the following structures:




19. The compound of any one of claims 1 to 18, wherein R is H, an optionally substituted C₁-C₁₈ alkyl group, or optionally substituted C₁-C₁₈ acyl group.

20. A method of synthesizing a compound according to any one of claims 1 to 19, comprising:


a) reacting an alkyl sultone of the formula V:



with a salt of thioacetate (AcS⁻M⁺) where M⁺ is a counter cation, to generate a compound of the formula VI:



b) reacting the product of a) with a compound of the formula VII:



where X'' is a halide, in an alcohol solvent and a polar solvent, using a base, to obtain said polyanionic cyclodextrin-based compound.

21. The method of 20, wherein L is $-(\text{CH}_2)_w-$, where w is 1 to 3; R is H; and G is $-\text{S}-$, and p is 6 to 8.
22. The method of claim 20 or 21, wherein the counter cation is Na^+ or K^+ .
23. The method of any one of claims 20 to 22, wherein the halide is Cl, Br or I.
24. The method of any one of claims 20 to 23, wherein the alcohol solvent is methanol.
25. The method of any one of claims 20 to 24, wherein the base is an alkoxide.
26. The method of any one of claims 20 to 25, wherein the polar solvent is DMSO.
27. A non-ionic cyclodextrin-based compound of the formula



wherein:

X° is one or more neutral moieties,


L is one or more linkers,

G is a bond or is one or more bridging groups,

D is a cyclodextrin and

R is a substituent.

28. The compound of claim 27, wherein the compound is:




(Formula IV)

wherein p is 6 (α -cyclodextrin), 7 (β -cyclodextrin) or 8 (γ -cyclodextrin).

29. The compound of claim 27 or 28, wherein X° is a substituted or unsubstituted amide, a nitrile group ($-\text{CN}$), or a polyhydroxylated residue.


30. The compound of claim 29, wherein the substituted or unsubstituted amide is –CONH₂.
31. The compound of claim 29, wherein the polyhydroxylated residue is a carbohydrate.
32. The compound of any one of claims 27 to 31, wherein G is –S–, –OC(O)–, –NHC(O)–, –SO–, –SO₂–, or a substituted or unsubstituted 1,2,3-triazole group.
33. The compound of claim 32, wherein the 1,2,3-triazole group is substituted with one of the following structures:



34. The compound of any one of claims 27 to 31, wherein G is a bond.
35. The compound of any one of claims 27 to 34, wherein L comprises a substituted or unsubstituted alkyl group, a substituted or unsubstituted polyethylene glycol (PEG) group, or a combination of one or more alkyl groups and one or more PEG groups.
36. The compound of claim 35, wherein the PEG group is of the formula –CHZ(CH₂OCHZ)_mCH₂–, where Z is H or CH₃ and m is 1 to 20.
37. The compound of claim 35 or 36, wherein the alkyl group is substituted with the PEG group.
38. The compound of claim 35 or 36, wherein the PEG group is substituted with the alkyl group.
39. The compound of any one of claims 35 to 38, wherein L comprises the PEG group flanked by one or more alkyl groups on either or both sides of the PEG group.
40. The compound of any one of claims 35 to 39, wherein the alkyl group is a C₁-C₁₁ alkyl group.
41. The compound of any one of claims 35 to 40, wherein one or more of the CH₂ groups of the alkyl group is replaced with an atom or functional group.

42. The compound of claim 41, wherein the atom or functional group is $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-CONH-$, $-COO-$, $-NZ-$, or a substituted or unsubstituted 1,2,3-triazole.

43. The compound of claim 41, wherein the 1,2,3-triazole group is substituted with one of the following structures:



44. The compound of any one of claims 27 to 43, wherein R is H, an optionally substituted C_1-C_{18} alkyl group, or optionally substituted C_1-C_{18} acyl group.

45. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein:

p is 6 (α -cyclodextrin), 7 (β -cyclodextrin) or 8 (γ -cyclodextrin);

X is $-CO_2^-$ or $-SO_3^-$;

G is $-S-$;

L is $-(CH_2)_k-$, where k is 7 to 11;

R is H.


46. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein

p is 6 (α -cyclodextrin), 7 (β -cyclodextrin) or 8 (γ -cyclodextrin);


X is $-CO_2^-$ or $-SO_3^-$;

G is $-S-$;

L is $-(CH_2)_k-$, where k is 1 to 11, or L is



where q is 0 to 20 and n is 1-5, or



, where l is 1-20; and

R is H, an optionally substituted C_1-C_{18} alkyl, or an optionally substituted C_1-C_{18} acyl.

47. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein

p is 6,

L is $-\zeta-(CH_2)_k-\zeta-$, where k is 1 to 11;

X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is $\text{C}_1\text{-C}_{18}$ alkyl or $\text{C}_1\text{-C}_{18}$ acyl.

48. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein

p is 6,


L is $-\xi-(\text{CH}_2)_k-\xi-$, where k is 7 to 11,

X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is H, $\text{C}_1\text{-C}_{18}$ alkyl, or $\text{C}_1\text{-C}_{18}$ acyl.

49. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein

p is 6,

L is , where q is 0 to 20 and n is 1 to 5

X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is H, $\text{C}_1\text{-C}_{18}$ alkyl, or $\text{C}_1\text{-C}_{18}$ acyl.

50. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein

p is 7,

L is $-\xi-(\text{CH}_2)_k-\xi-$, where k is 1 to 11;

X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is $\text{C}_1\text{-C}_{18}$ alkyl, or $\text{C}_1\text{-C}_{18}$ acyl.

51. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein

p is 7,


L is $-\xi-(\text{CH}_2)_k-\xi-$, where k is 7 to 11;

X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is H, $\text{C}_1\text{-C}_{18}$ alkyl, or $\text{C}_1\text{-C}_{18}$ acyl.

52. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein


p is 7,



X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is H, C₁-C₁₈ alkyl, or C₁-C₁₈ acyl.


53. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein p is 8,



X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is C₁-C₁₈ alkyl, or C₁-C₁₈ acyl.


54. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein p is 8,



X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is H, C₁-C₁₈ alkyl, or C₁-C₁₈ acyl.

55. The polyanionic cyclodextrin-based compound of claim 1 or 2, wherein p is 8,



X is $-\text{CO}_2^-$ or $-\text{SO}_3^-$;

and R is H, C₁-C₁₈ alkyl, or C₁-C₁₈ acyl.

56. A pharmaceutical composition comprising a medicament and a compound of any one of claims 1 to 19 and 27 to 55.

57. An excipient comprising the compound of any one of claims 1 to 19 and 27 to 55.




FIGURE 1




FIGURE 2




FIGURE 3





FIGURE 4



$\text{R} = -\text{G-L-X}^- \text{Y}^+$ (such as $-\text{S-G-L-X}^- \text{Y}^+$) or $-\text{OH}$.

FIGURE 6

7/19




FIGURE 7





FIGURE 8



$\text{R} = -\text{G-L-X}'$ (such as $-\text{S-G-L-X}'$) or $-\text{OH}$.

FIGURE 9




FIGURE 10

¹H NMR Spectrum of Polyanionic α -CD Derivative (28) in D₂O




FIGURE 11

¹H NMR Spectrum of Polyanionic α -CD Derivative (28) in D₂O




FIGURE 12

¹H NMR Spectrum of Polyanionic β-CD Derivative (29) in D₂O




FIGURE 13

¹H NMR Spectrum of Polyanionic γ -CD Derivative (30) in D₂O, 600 MHz




FIGURE 14

¹H NMR Spectrum of non-ionic γ -CD polyamide derivative (39) in D₂O, 600 MHz




FIGURE 15

¹H NMR Spectrum of non-ionic γ -CD polyamide derivative (43) in D₂O, 600 MHz




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2015/050254

A. CLASSIFICATION OF SUBJECT MATTER
 IPC: **C08B 37/16** (2006.01), **A61K 47/40** (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC: **C08B 37/16** (2006.01), **A61K 47/40** (2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
 STN (Chemical structure), PubMed, Questel Orbit, Canadian Patent Database.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US2010056475A1, (CHUCHOŁOWSKI et al.) 04 March 2010 (04-03-2010)	1-5, 7, 10-11, 15, 19, 46, 50, 56, 57
X	US8492538B1, (MATOS) 23 July 2013 (23-07-2013)	1-6, 9-11, 15, 19, 46, 50, 56, 57
X	US2009270348A1, (ANTLE) 29 October 2009 (29-10-2009)	1-6, 9-11, 15, 19, 46, 50, 56, 57
X	US6672340B2, (ZHANG et al.) 06 January 2004 (06-01-2004)	1-7, 9-19, 46, 47, 50, 53, 56, 57

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
 16 July 2015 (16-07-2015)

Date of mailing of the international search report
 20 July 2015 (20-07-2015)

Name and mailing address of the ISA/CA
 Canadian Intellectual Property Office
 Place du Portage I, C114 - 1st Floor, Box PCT
 50 Victoria Street
 Gatineau, Quebec K1A 0C9
 Facsimile No.: 001-819-953-2476

Authorized officer

Jim Martyn (819) 953-0761

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.: 16-18
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 16-18 do not contain all the limitations of the claim to which they depend, thus rendering the scope of these claims unclear.

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
See Extra Sheet:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos.:

Group A - Claims 1-7 (in part), 9-19 (in part), 46-57 (in part) are directed to cyclodextrin derivatives wherein G is a sulfur, L is an ethylene glycol derivative and X is anionic;

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2015/050254

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ADAM et al.; Cyclodextrin-Derived Host Molecules as Reversal Agents for the Neuromuscular Blocker Rocuronium Bromide: Synthesis and Structure-Activity Relationships; J. Med. Chem.; 2002, vol. 45, pp 1808-1816	1-7, 9-19, 46, 47, 50, 53, 56, 57
X	ZHONG et al.; Selective Removal of Palmitic Acid from Langmuir Monolayers by Complexation with New Quaternary Ammonium α -Cyclodextrin Derivatives; Langmuir, 2001, Vol. 17; pp 5319-5323	1-3, 5, 7, 9-15, 19
X	NELLES et al.; Controlled Orientation of Cyclodextrin Derivatives Immobilized on Gold Surfaces; J. Am Chem. Soc., 1996, Vol. 118, pp 5039-5046	1-3, 5, 7, 9, 15, 19
X	QIAN et al.; Superstructures of Cyclodextrin Derivatives on Au(111): A Combined Random Planting-Molecular Dynamics Approach; Langmuir, 1997, Vol. 13, pp 7092-7098	1-5, 7, 9-19
X	SIGURSKJOLD et al.; Thermodynamics of Binding of Heterobidentate Ligands Consisting of Spacer-Connected Acarbose and α -Cyclodextrin to the Catalytic and Starch-Binding Domains of Glucoamylase from <i>Aspergillus niger</i> Shows That the Catalytic and Starch-Binding Sites Are in Close Proximity in Space; Biochemistry, 1998, Vol. 37, pp 10446-10452	1-5, 7, 9-19
X	GARCIA-BARRIENTOS et al.; Synthesis of β -Cyclodextrin, Per-O-glycosylated through an Ethylene Glycol Spacer Arm; Synthesis, 2001, No. 7, pp 1057-1064	1-5, 7, 9-19
X	DRIGUES ET AL.; Stability and function of interdomain linker variants of glucoamylase 1 from <i>Aspergillus niger</i> ; Biochemistry; 2001, Vol. 40, pp 9336-9346	1-5, 7, 9-19
X	WANG et al.; Topochemical control of the photodimerization of aromatic compounds by γ -cyclodextrin thioethers in aqueous solution, Beilstein J. Org. Chem., 2013, Vol. 9, pp1858-1866	1-7, 9, 11, 13, 15, 19

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2015/050254

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
US2010056475A1	04 March 2010 (04-03-2010)	US2010056475A1 WO2010017328A2 WO2010017328A3	04 March 2010 (04-03-2010) 11 February 2010 (11-02-2010) 13 January 2011 (13-01-2011)
US8492538B1	23 July 2013 (23-07-2013)	US8492538B1 US2014046061A1	23 July 2013 (23-07-2013) 13 February 2014 (13-02-2014)
US2009270348A1	29 October 2009 (29-10-2009)	US2009270348A1 US7635773B2 AU2009241858A1 BRPI0905080A2 CA2702603A1 CA2702603C CA2771879A1 CN101959508A EA201000828A1 EP2268269A2 EP2268269A4 IL208956D0 JP2010539193A JP4923144B2 JP2012072160A KR20110010742A KR101314803B1 MX2010004900A NZ589290A US2010093663A1 US8410077B2 US2013184357A1 WO2009134347A2 WO2009134347A3	29 October 2009 (29-10-2009) 22 December 2009 (22-12-2009) 05 November 2009 (05-11-2009) 30 June 2015 (30-06-2015) 05 November 2009 (05-11-2009) 19 June 2012 (19-06-2012) 05 November 2009 (05-11-2009) 26 January 2011 (26-01-2011) 31 October 2011 (31-10-2011) 05 January 2011 (05-01-2011) 17 August 2011 (17-08-2011) 31 January 2011 (31-01-2011) 16 December 2010 (16-12-2010) 25 April 2012 (25-04-2012) 12 April 2012 (12-04-2012) 07 February 2011 (07-02-2011) 10 October 2013 (10-10-2013) 07 June 2010 (07-06-2010) 21 December 2012 (21-12-2012) 15 April 2010 (15-04-2010) 02 April 2013 (02-04-2013) 18 July 2013 (18-07-2013) 05 November 2009 (05-11-2009) 14 January 2010 (14-01-2010)
US6672340B2	06 January 2004 (06-01-2004)	US2002053365A1 AR031179A1 AU780070B2 AU8924301A BR0105077A CA2358583A1 CA2358583C DE50113779D1 EP1205704A1 EP1205704B1 JP2002206693A JP4030745B2	09 May 2002 (09-05-2002) 10 September 2003 (10-09-2003) 24 February 2005 (24-02-2005) 12 September 2002 (12-09-2002) 25 June 2002 (25-06-2002) 08 May 2002 (08-05-2002) 13 July 2004 (13-07-2004) 08 May 2008 (08-05-2008) 15 May 2002 (15-05-2002) 26 March 2008 (26-03-2008) 26 July 2002 (26-07-2002) 09 January 2008 (09-01-2008)

Continued from Box III

Group A - Claims 1-7 (in part), 9-19 (in part), 46-57 (in part) are directed to cyclodextrin derivatives wherein G is a sulfur, L is an ethylene glycol derivative and X is anionic;

Group B - Claims 27-32, 34-44 (in part), 56-57 (in part) are directed to cyclodextrin derivatives wherein G is a sulfur, L is alkyl and X is neutral;

Group C - Claims 1-7 (in part), 9-19 (in part), 20-26, 45, 46-57 (in part) are directed to cyclodextrin derivatives wherein G is a sulfur, L is alkyl and X is anionic;

Group D - Claims 27-32, 34-44 (in part), 56-57 (in part) are directed to cyclodextrin derivatives wherein G is a sulfur, L is an ethylene glycol derivative and X is neutral;

Group E - Claims 1-7 (in part), 8, 9-19 (in part), 46-57 (in part) are directed to cyclodextrin derivatives wherein G is a triazole, L is alkyl and X is anionic;

Group F - Claims 27-32 (in part), 33, 34-44 (in part), 56-57 (in part) are directed to cyclodextrin derivatives wherein G is a triazole, L is alkyl and X is neutral;

Group G - Claims 1-7 (in part), 8, 9-19 (in part), 46-57 (in part) are directed to cyclodextrin derivatives wherein G is a triazole, L is an ethylene glycol derivative and X is anionic; and

Group H - Claims 27-32 (in part), 33, 34-44 (in part), 56-57 (in part) are directed to cyclodextrin derivatives wherein G is a triazole, L is an ethylene glycol derivative and X is neutral.